Novavax COVID-19 vaccine demonstrated 90% overall efficacy and 100% protection in phase 3 trial
On Jun. 14, 2021, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against…
NIH launched clinical trial of universal influenza vaccine candidate
On Jun. 1, 2021, a first-in-human, Phase 1 trial assessing the safety and immunogenicity of an investigational nanoparticle…
Celsion filed provisional U.S. patent application for broad range of next generation DNA vaccines
On Jan. 28, 2021, Celsion announced the filing of a provisional U.S. patent application for a novel DNA-based,…
Baxter Biopharma Solutions announced sterile manufacturing agreement for Novavax COVID-19 vaccine
On Jan. 11, 2021, Baxter announced an agreement to provide sterile manufacturing services for NVX-CoV2373, Novavaxï¾’ COVID-19 recombinant…
NIH neuroscientists isolated promising mini antibodies against COVID-19 from a llama
On Dec. 22, 2020, the NIH researchers announced they had isolated a set of promising, tiny antibodies, or…
Matinas BioPharma announced collaboration with NIAID to evaluate Gilead’s antiviral remdesivir
On Dec. 7, 2020, Matinas BioPharma announced that they planned to collaborate with the National Institute of Allergy…
Novavax provided phase 3 COVID-19 vaccine clinical development update
On Oct. 27, 2020, Novavax announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19…
Amyris and the Infectious Disease Research Institute entered into exclusive license for novel RNA vaccine platform
On Oct. 22, 2020, Amyris and the Infectious Disease Research Institute (IDRI) announced the signing of a Collaboration…
Alberta Enterprise Corporation invested additional $5 million to benefit Alberta startups
On Oct. 19, 2020, Alberta Enterprise announced that it had invested an additional $5 million into its third…
Evaluation of LamPORE rapid tests for Covid-19 showed high levels of diagnostic sensitivity
On Sept. 25, 2020, scientists from the University of Oxfordï¾’s Nuffield Department of Medicine published their evaluation of…
NanoViricides nominated a novel candidate for advancing Into clinical trials for treatment of COVID-19
On Sept. 16, 2020, NanoViricides announced that it had nominated a clinical drug candidate for the treatment of…
Novavax announced COVID-19 vaccine manufacturing agreement with Serum Institute of India
On Sept. 15, 2020, Novavax announced an amendment to its existing agreement with Serum Institute of India which…
Novavax announced COVID-19 vaccine manufacturing agreement with Serum Institute of India
On Sept. 15, 2020, Novavax announced an amendment to its existing agreement with Serum Institute of India. With…
Novavax initiated phase 2 portion of phase 1/2 clinical trial of COVID-19 vaccine
On Aug. 24, 2020, Novavax announced that the first volunteers were enrolled in the Phase 2 portion of…
Novavax initiated efficacy trial of COVID-19 vaccine in South Africa
On Aug. 17, 2020, Novavax announced the beginning of a Phase 2b clinical trial in South Africa to…
Novavax and Takeda announced collaboration for Novavax COVID-19 vaccine candidate in Japan
On Aug. 7, 2020, Novavax and Takeda Pharmaceutical announced a partnership for the development, manufacturing and commercialization of…
Novavax and Serum Institute of India announced development and commercial collaboration
On Aug. 6, 2020, Novavax announced a license agreement with Serum Institute of India Private Limited (SIIPL) for…
HDT BIOï¾’s COVID-19 vaccine candidate HDT-301 induced neutralizing antibody responses after single injection
On Jul. 20, 2020, scientists at HDT Bio, PAI Life Sciences, and the University of Washington announced they…
Engineered llama antibodies neutralised Covid-19 virus
On Jul. 13, 2020, a team of researchers from Oxford University, the Rosalind Franklin Institute, Diamond Light Source…
NanoViricides reported safety and tolerability of anti-Coronavirus drug candidates observed in animal model
On Jul. 8, 2020, NanoViricides announced that excellent safety and tolerability of the drug candidates it is developing…
Novavax announced $1.6 billion funding from Operation Warp Speed
On Jul. 7, 2020, Novavax announced that it has been selected to participate in Operation Warp Speed, a…
Novavax awarded Department of Defense contract for COVID-19 vaccine
On Jun. 4, 2020, Novavax announced that the company had been awarded a contract by the U.S. Department…
Novavax expanded large-scale global manufacturing capacity
On May 27, 2020, Novavax announced the acquisition of Praha Vaccines a.s., part of the Cyrus Poonawalla Group,…
Novavax initiated phase 1/2 clinical trial of COVID-19 vaccine
On May 26, 2020, Novavax announced enrollment of the first participants in a Phase 1/2 clinical trial of…
Roche acquired Stratos Genomics to further develop DNA based sequencing for diagnostic use
On May 22, 2020, Roche announced that it had acquired Seattle-based Stratos Genomics, an early-stage sequencing technology company…
Llama antibody engineered to block Coronavirus
On May 19, 2020, the NIH rported that researchers from the University of Texas, in collaboration with a…
Predictive Oncology licensed NSP10 technology in the race to develop a vaccine for development
On May 14, 2020, Predictive Oncology announced the acquisition of Soluble Therapeutics and the subsequent partnership and licensing…
Biotechnology | COVID-19 | Life Science News | Nanotechnology | Pharmaceutical | Therapeutics | Vaccine
Entos Pharma partnered with Precision NanoSystems to enable scalable GMP manufacturing of Fusogenix DNA COVID-19 vaccine
On May 7, 2020, Entos Pharmaceuticals announced a partnership with PrecisionNanoSystems (PNI) to produce clinica lgrade vaccines and…
Predictive Oncology launched new AI platform for vaccine and drug development targeting coronaviruses and Acute Respiratory Syndromes
On May 6, 2020, Predictive Oncology announced the acquisition of Soluble Therapeutics and partnership and licensing of a…
ARTES joined global combat against Corona with virus-like particle based platform technologies
On Apr. 27, 2020, ARTES Biotechnology, the German-based biotech company specializing in process development for recombinant vaccines, entered…